[Current therapy of lupus nephritis] (Q78679215)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

review article

1 reference

title

[Current therapy of lupus nephritis] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

Josep Font

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Manuel Ramos Casals

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

738-742

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

Prognosis in systemic lupus erythematosus

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Systemic lupus erythematosus--disease management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Treatment of lupus nephritis: a meta-analysis of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Long-term treatment of lupus nephritis with cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Remission of systematic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

[Lupus nephropathy: implications of a long course]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Cardiovascular risk factors and the long-term outcome of lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

The very long-term prognosis and complications of lupus nephritis and its treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

The Long-Term Clinical Course of Systemic Lupus Erythematosus in End-Stage Renal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Maintenance hemodialysis in end-stage lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Correlation of renal histology with outcome in children with lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Renal transplantation for systemic lupus erythematosis: excellent long-term results with both living and cadaveric donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d'île de France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Increased vulnerability of the donor organ in related kidney transplants for certain diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Risk factors for renal allograft loss in patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

Advances in the treatment of lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2973561-6

10.1016/S0025-7753(02)73561-6

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12487971%20AND%20SRC:MED&resulttype=core&format=json